

HC2 HOLDINGS, INC.  
Form 8-K  
March 02, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934  
Date of Report (Date of earliest event reported): March 2, 2017

HC2 HOLDINGS, INC.

|  |                             |  |
|--|-----------------------------|--|
| Delaware   | 001-35210                   | 54-1708481                                 |
| (State or<br>other<br>jurisdiction<br>of<br>incorporation) | (Commission<br>File Number) | (IRS<br>Employer<br>Identification<br>No.) |

|  |               |
|--|---------------|
| 450 Park Avenue,<br>30th Floor<br>New York, NY | 10022         |
| (Address of<br>principal<br>executive offices) | (Zip<br>Code) |

(212) 235-2690  
(Registrant's telephone number, including  
area code)

Not Applicable  
(Former name or former address, if  
changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On March 2, 2017, HC2 Holdings, Inc. issued a press release entitled "HC2 Portfolio Company MEDIBEACON™ Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor", a copy of which is attached as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

| Item No. | Description  |
|----------|--|
| 99.1     | Press Release dated March 2, 2017, entitled "HC2 Portfolio Company MEDIBEACON™ Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor" |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 2, 2017

HC2 Holdings, Inc.

(Registrant)

By: /s/ Paul L. Robinson

Name: Paul L. Robinson

Title: Chief Legal Officer and Corporate Secretary

Exhibit Index

| Item No. | Description  |
|----------|--|
| 99.1     | Press Release dated March 2, 2017, entitled "HC2 Portfolio Company MEDIBEACON™ Inc. Completes Successful Clinical Study of Groundbreaking Kidney Function Monitor" |